EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access

The Effects of Immune Checkpoint Inhibitors on Hidradenitis Suppurativa: A Scoping Review

Camila R Marquez, Marie P Vetter, Vivian Y Shi, Anna L Cogen

Skin Appendage Disorders · 23.06.2026 · 1-9

DOI: 10.1159/000551945 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Skin Appendage Disorders, online erschienen am 23.06.2026. Verfasst von Camila R Marquez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Washington School of Medicine, Seattle, WA, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hidradenitis suppurativa (HS) is a debilitating skin disease marked by recurrent abscesses and chronic inflammation. Immune checkpoint inhibitors (ICIs) are widely used oncologic treatments that can provoke immune-mediated effects. The ICI potential to precipitate HS onset or influence HS disease activity remains uncharacterized. We aim to characterize the timing, clinical features, severity, and outcomes of HS in this context.

Methods

Scoping review according to PRISMA guidelines was conducted. Studies were identified through PubMed and MEDLINE searches and were eligible if they reported at least 1 case of HS onset or worsening in the setting of ICI therapy.

Results

Five publications comprising 13 patients were included. Pembrolizumab was the most frequently used ICI (46.2%). Eight individuals (61.5%) had pre-existing HS, of whom 3 (37.5%) experienced flares during therapy. Five patients (38.5%) developed new-onset HS after ICI initiation, within 2–4 months. Treatment approaches varied and included topical and systemic therapies for HS. Four patients (30.8%) experienced complete resolution of HS lesions following ICI discontinuation.

Conclusions

ICI therapy may precipitate new-onset HS or exacerbate pre-existing disease in a subset of patients. Increased clinical vigilance and early dermatologic involvement may support timely diagnosis, optimize management, and preserve continuity of oncologic care.

Schlagwörter

Stichwörter der Autor:innen

Cancer treatmentHidradenitis suppurativaImmune checkpoint inhibitorsImmunotherapy

Autor:innen und Institutionen

  • Department of Dermatology, University of Washington School of Medicine, Seattle, WA, USA.
  • University of Illinois College of Medicine, Chicago, IL, USA.
  • University of Washington School of Medicine, Seattle, WA, USA.

Zitieren

APA

Marquez, C. R., Vetter, M. P., Shi, V. Y., & Cogen, A. L. (2026). The Effects of Immune Checkpoint Inhibitors on Hidradenitis Suppurativa: A Scoping Review. Skin Appendage Disorders, 1-9. https://doi.org/10.1159/000551945

Vancouver

Marquez CR, Vetter MP, Shi VY, Cogen AL. The Effects of Immune Checkpoint Inhibitors on Hidradenitis Suppurativa: A Scoping Review. Skin Appendage Disorders. 2026:1-9. doi:10.1159/000551945

BibTeX
@article{Marquez2026,
  author = {Marquez, Camila R and Vetter, Marie P and Shi, Vivian Y and Cogen, Anna L},
  title = {The Effects of Immune Checkpoint Inhibitors on Hidradenitis Suppurativa: A Scoping Review},
  journal = {Skin Appendage Disorders},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000551945}
}
Kostenlos starten →